Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 85
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Arch Orthop Trauma Surg ; 142(5): 763-768, 2022 May.
Article in English | MEDLINE | ID: mdl-33389020

ABSTRACT

INTRODUCTION: Cementless femoral revision total hip arthroplasty (RTHA) after periprosthetic fracture, aseptic loosening or infection is a challenging surgical procedure. The aim of this study was to evaluate the incidence and reasons for failure after two-stage septic revision, periprosthetic fracture or aseptic loosening that may reveal a rationale for cementless RTHA in two-stage revisions. MATERIALS AND METHODS: A consecutive series of 105 cases using cementless femoral revision prostheses were evaluated retrospectively. Indications for revision were 39 two-stage revisions after infection, 49 aseptic loosenings, and 17 periprosthetic fractures. A Kaplan-Meier analysis was performed using infection with or without removal of the implant as an endpoint. RESULTS: Incidence of infection with or without implant removal was significantly higher in patients treated for periprosthetic fractures compared to two-stage revisions or aseptic loosening (log-rank P < 0.0001). The mean follow-up period was 6.4 (2.0-13.7) years. Using infection with or without implant removal as the endpoint, 12 patients were diagnosed after the index operation resulting in a cumulative risk after 13.7 years of 29.9% (95% CI 0-61.2). CONCLUSION: Cementless revision using a modular tapered device is reliable with respect to reinfection risk in two-stage procedures.


Subject(s)
Arthroplasty, Replacement, Hip , Hip Prosthesis , Periprosthetic Fractures , Arthroplasty, Replacement, Hip/methods , Follow-Up Studies , Hip Prosthesis/adverse effects , Humans , Periprosthetic Fractures/epidemiology , Periprosthetic Fractures/etiology , Periprosthetic Fractures/surgery , Prosthesis Design , Prosthesis Failure , Reoperation/adverse effects , Retrospective Studies , Risk Factors
2.
Arch Orthop Trauma Surg ; 139(6): 877-881, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30972480

ABSTRACT

To clarify the role of concomitant carpal lesions in dislocated distal radius fractures (DRF), 104 consecutive patients with DRF underwent a preoperative morphological examination using CT and MRI. The study was performed between 2004 and 2006 with the aim of recording all types of concomitant carpal lesions as well as their consequences after 1 year. Carpal lesions of different types were found in all treated cases of dislocated DRF. A clinical follow-up 1 year (13.9 ± 6.5 months) after surgical treatment showed no correlation between the carpal lesions and the treatment outcome (previously described by Gologan et al. 2011). A second follow-up study ( > 10 years postoperative, range 11.2 ± 0.9 years) was initiated to find suspected later decompensations of the concomitant carpal lesions. A total of 37 of the original 104 patients could potentially be followed up: 22 patients had passed through both follow-ups and 15 could only be contacted with restrictions. 27 patients had died, 24 patients were excluded due to the presence of dementia or explicit rejection, and 16 patients could no longer be found. Using the Castaing score, the first follow-up after 1 year resulted in an average of 4.95 ± 3.1 points (range 0-12; "good result") and the second follow-up after 10 years in an average of 5.91 ± 2.9 points (range 2-14; "good result"). Again, there were no correlations with the primarily recognized carpal lesions [comparable groups 22 vs 22 (identical patients in both follow-ups); lost to follow-up rate 15.4%]. These results suggest that concomitant carpal lesions are primarily prevalent and detectable in (nearly) all dislocated DRF cases. However, with the usual protection of the wrist and the carpus after surgical treatment of DRF, these lesions often do not decompensate or require treatment, even after 10 years.


Subject(s)
Carpal Bones , Joint Dislocations , Radius Fractures , Carpal Bones/diagnostic imaging , Carpal Bones/surgery , Follow-Up Studies , Humans , Joint Dislocations/diagnostic imaging , Joint Dislocations/surgery , Magnetic Resonance Imaging , Radius Fractures/diagnostic imaging , Radius Fractures/surgery , Tomography, X-Ray Computed , Treatment Outcome
3.
J Fish Biol ; 90(1): 61-79, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27723107

ABSTRACT

The population structure of the Pacific cod Gadus macrocephalus was examined using 15 microsatellite loci and mitochondrial DNA (ND2 region). In total, 274 individuals were sampled from 16 locations around Japan to estimate the level of genetic differentiation and effective population size (Ne ). Pairwise FST , analysis of molecular variance and Bayesian clustering analysis suggested the presence of two genetically distinct groups in waters around Japan, with a higher Ne value in the eastern group than in the western group. A possible factor that restricts gene flow between groups may be related to the water temperature differences in the south-western part of the Sea of Japan, where the Tsushima Warm Current flows around the area inhabited by the western group, which may limit migration between the west and east.


Subject(s)
Gadiformes/genetics , Genetic Variation , Animals , Bayes Theorem , DNA, Mitochondrial/genetics , Genetics, Population , Japan , Microsatellite Repeats/genetics , Pacific Ocean
4.
Arch Orthop Trauma Surg ; 136(10): 1343-8, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27447881

ABSTRACT

INTRODUCTION: Septic ankle joint arthrodesis is a good therapeutic option in cases of infection after trauma or orthopedic surgical procedures. Many different procedures have been described, but external fixation seems to be standard. Aim of this study is to identify risk factors for complications in septic ankle joint arthrodesis with the external AO frame fixator. MATERIALS AND METHODS: Patients who received septic ankle joint arthrodesis between January 2008 and December 2012 were included in this study. Patients were evaluated clinically and with radiographs or CT scans. RESULTS: Follow-up of 74 of 79 patients with an external AO frame fixator could be evaluated; follow-up was 411 days (105-991). The mean age at surgery was 57.7 years (19-87). At this time, complications occurred in 41 patients (52 %) with wound healing problems (17 patients, 22 %) and non-union (12 patients, 15 %), and some needed surgical revision. In our collective, men had a significant higher non-union rate (p = 0.031), age or BMI showed no difference. Patients with diabetes and alcohol consumption showed a higher risk for complications (p = 0.049 and p = 0.031, respectively). 62 % of primary arthrodesis showed union, whereas in the case of revision, arthrodesis only 39 % showed union. CONCLUSIONS: Septic ankle joint arthrodesis with the external AO frame fixator is a probable tool to achieve union. This study showed that there is a high complication rate and some risk factors for complications could be identified. A blinded and prospective study is needed to compare intramedullary nailing and external fixation to evaluate the possible advantage of intramedullary devices in septic ankle arthrodesis.


Subject(s)
Ankle Joint/surgery , Arthritis, Infectious/surgery , Arthrodesis , Postoperative Complications/etiology , Adult , Aged , Aged, 80 and over , Arthritis, Infectious/complications , Arthrodesis/instrumentation , Arthrodesis/methods , External Fixators , Female , Follow-Up Studies , Humans , Male , Middle Aged , Postoperative Complications/epidemiology , Retrospective Studies , Risk Factors , Treatment Outcome
5.
J Antimicrob Chemother ; 69(12): 3311-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25096076

ABSTRACT

OBJECTIVES: To assess the effect of the major efavirenz metabolizing enzyme (CYP2B6) genotype and the effects of rifampicin co-treatment on induction of CYP3A by efavirenz. PATIENTS AND METHODS: Two study arms (arm 1, n = 41 and arm 2, n = 21) were recruited into this study. In arm 1, cholesterol and 4ß-hydroxycholesterol were measured in HIV treatment-naive patients at baseline and then at 4 and 16 weeks after initiation of efavirenz-based antiretroviral therapy. In arm 2, cholesterol and 4ß-hydroxycholesterol were measured among patients taking efavirenz during rifampicin-based tuberculosis (TB) treatment (efavirenz/rifampicin) just before completion of TB treatment and then serially following completion of TB treatment (efavirenz alone). Non-linear mixed-effect modelling was performed. RESULTS: A one-compartment, enzyme turnover model described 4ß-hydroxycholesterol kinetics adequately. Efavirenz treatment in arm 1 resulted in 1.74 (relative standard error = 15%), 3.3 (relative standard error = 33.1%) and 4.0 (relative standard error = 37.1%) average fold induction of CYP3A for extensive (CYP2B6*1/*1), intermediate (CYP2B6*1/*6) and slow (CYP2B6*6/*6) efavirenz metabolizers, respectively. The rate constant of 4ß-hydroxycholesterol formation [mean (95% CI)] just before completion of TB treatment [efavirenz/rifampicin co-treatment, 7.40 × 10(-7) h(-1) (5.5 × 10(-7)-1.0 × 10(-6))] was significantly higher than that calculated 8 weeks after completion [efavirenz alone, 4.50 × 10(-7) h(-1) (4.40 × 10(-7)-4.52 × 10(-7))]. The CYP3A induction dropped to 62% of its maximum by week 8 of completion. CONCLUSIONS: Our results indicate that efavirenz induction of CYP3A is influenced by CYP2B6 genetic polymorphisms and that efavirenz/rifampicin co-treatment results in higher induction than efavirenz alone.


Subject(s)
Anti-HIV Agents/pharmacokinetics , Antitubercular Agents/pharmacokinetics , Benzoxazines/pharmacokinetics , Cytochrome P-450 CYP2B6/genetics , Cytochrome P-450 CYP3A/metabolism , Hydroxycholesterols/analysis , Rifampin/pharmacokinetics , Adult , Alkynes , Anti-HIV Agents/therapeutic use , Antitubercular Agents/therapeutic use , Benzoxazines/therapeutic use , Cyclopropanes , Female , Genotype , HIV Infections/drug therapy , Humans , Male , Middle Aged , Rifampin/therapeutic use , Tuberculosis/drug therapy
6.
Arch Orthop Trauma Surg ; 134(12): 1655-60, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25308148

ABSTRACT

INTRODUCTION: The aim of the study was to determine predictive risk factors for revision surgery in patients with septic orthopaedic implant removal of the lower leg. MATERIALS AND METHODS: A total of 196 patients with septic removal of orthopaedic implants after primary trauma of the lower leg between 2008 and 2012 were evaluated. Patients with endoprosthesis infection were excluded from this study. RESULTS: Thirteen patients (22.4 %) had infectious complications with revision surgery. We found 14 patients with soft tissue infections, 10 patients with osteomyelitis, 19 patients with wound-healing problems, 10 patients with pin track infections and two patients with fistulas. High complication rates were associated with severity of the initial trauma, localisation, and the state of union or non-union. Patients with peripheral arterial disease, anaemia and smoking showed a significantly higher risk for revision surgery; whereas patients with diabetes and arterial hypertension did not. A total of 22.6 % had open fractures as an initial trauma. In 76 %, bacteria could be detected. The complication rate was 41.2 % after initial open fractures and 19.6 % after initial closed fractures. A higher grade of soft tissue damage showed no increasing complication rate (p > 0.05). CONCLUSIONS: In this study, complications after septic implant removal of the lower leg were evaluated and risk factors were determined. The awareness of the risks for complications after septic orthopaedic implant removal can lead to a better treatment for patients. Decision-making can be based on scientific results to prevent patients suffering from further severe disease progression.


Subject(s)
Fibula/injuries , Fractures, Bone/surgery , Leg Injuries/surgery , Prosthesis-Related Infections/surgery , Tibial Fractures/surgery , Adolescent , Adult , Aged , Device Removal , Female , Fracture Healing , Fractures, Closed/surgery , Fractures, Open/surgery , Humans , Male , Middle Aged , Osteomyelitis/surgery , Prosthesis-Related Infections/epidemiology , Reoperation , Retrospective Studies , Risk Factors , Soft Tissue Infections/surgery
7.
Unfallchirurg ; 117(1): 61-9; quiz 70-1, 2014 Jan.
Article in German | MEDLINE | ID: mdl-24445994

ABSTRACT

Soft tissue defects in the distal lower leg region are challenging to treat, especially in trauma cases. To achieve early closure of the defect, pediculated adipofascial or muscle flaps can be used as well as free flaps. The pediculated adipofascial suralis flap has a reliable blood supply and a broad radius so this flap can be used for almost every defect location on the distal lower leg except for defects larger than 10 × 10 cm. The donor site defect does not lead to major problems and is well tolerated. The soleus flap can cover defects in the middle third and proximal distal third of the lower leg with its muscle. The donor site defect is occasionally associated with reduced calf functioning but is tolerated well most of the time. Because of these advantages, the pediculated adipofacial suralis flap and the soleus muscle flap can be used instead a microvascular free flap for the closure of defects in the distal lower leg region.


Subject(s)
Leg Injuries/surgery , Plastic Surgery Procedures/instrumentation , Plastic Surgery Procedures/methods , Soft Tissue Injuries/surgery , Surgical Flaps , Humans
8.
Lupus ; 22(5): 497-503, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23554038

ABSTRACT

SH2D1A, also known as signaling lymphocytic activation molecule (SLAM)-associated protein (SAP), is an adaptor protein. Recently, it was reported that SAP deficient mice were protected from systemic lupus erythematosus (SLE). In this study, we postulated SH2D1A gene to be a candidate susceptibility gene for SLE and analyzed its association with SLE. A case-control association study was conducted on 5 tag single nucleotide polymorphisms (SNPs) in SH2D1A region in 506 Japanese female SLE patients and 330 healthy female controls. The luciferase assay was performed to determine the functional role of the SNP associated with SLE. One SNP in the intron 2, rs2049995, showed association with SLE (p=0.0110, odds ratio (OR) 1.97, 95% confidence interval (CI) 1.16-3.34, under the dominant model). The association of rs2049995 seemed to be stronger in the subset with the age of onset less than 20 years (p=0.0067, OR 2.65, 95% CI 1.28-5.46). Functional evaluation of rs2049995 showed that reporter gene activity was increased 1.9-fold for the susceptible allele compared with the resistant allele. An intronic SNP of SH2D1A is associated with SLE.


Subject(s)
Intracellular Signaling Peptides and Proteins/genetics , Lupus Erythematosus, Systemic/genetics , Adult , Asian People , Case-Control Studies , Female , Genetic Predisposition to Disease , Humans , Intracellular Signaling Peptides and Proteins/metabolism , Introns , Japan , Jurkat Cells , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Luciferases , Lupus Erythematosus, Systemic/metabolism , Middle Aged , Polymorphism, Single Nucleotide , Signaling Lymphocytic Activation Molecule Associated Protein
9.
Pharmacogenomics J ; 12(6): 499-506, 2012 Dec.
Article in English | MEDLINE | ID: mdl-21862974

ABSTRACT

The objective of this study was to assess the incidence, timing and identify pharmacogenetic, efavirenz (EFV) pharmacokinetic and biochemical predictors of EFV-based antiretroviral therapy (ART) drug-induced liver injury (DILI). ART-naïve HIV patients (n = 285) were prospectively enrolled. Pretreatment laboratory evaluations included hepatitis B surface antigen and C antibody, CD4 count and viral load. Liver tests were done at baseline, 1st, 2nd, 4th, 8th, 12th, 24th and 48th weeks during ART. Plasma EFV and 8-hydroxyefvairenz concentration was determined at week 4 using liquid chromatography-mass spectrometry. CYP2B6, CYP3A5, ABCB1 3435C/T and UGT2B7*2 genotyping was done using Taqman genotyping assay. Data were analyzed using survival analysis and Cox proportional hazards model. The incidence of DILI was 15.7% or 27.9 per 100 person-years and that of severe injury was 3.4% or 6.13 per 100 person-years. The median time for the development of DILI and severe injury was 2 and 4 weeks after initiation of ART, respectively. There was significant association of DILI with lower baseline platelet, albumin, log plasma viral load and CD4 count (P = 0.031, 0.037, 0.06 and 0.019, respectively). Elevated baseline alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, plasma EFV level and CYP2B6*6 were good predictors for the development of DILI (P = 0.03, 0.01, 0.016, 0.017 and 0.04, respectively). We report for the first time CYP2B6*6 as a putative genetic marker and high plasma EFV concentration as intermediate biomarker for vulnerability to EFV-induced liver injury in HIV patients. CYP2B6 genotyping and/or regular monitoring of EFV and lever enzymes level during early therapy is advised for early diagnosis and management of DILI.


Subject(s)
Antiretroviral Therapy, Highly Active/adverse effects , Aryl Hydrocarbon Hydroxylases/genetics , Benzoxazines/adverse effects , Chemical and Drug Induced Liver Injury/genetics , HIV Infections/drug therapy , Oxidoreductases, N-Demethylating/genetics , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Adult , Alkynes , Benzoxazines/blood , Cohort Studies , Cyclopropanes , Cytochrome P-450 CYP2B6 , Cytochrome P-450 CYP3A/genetics , Female , Genotype , Humans , Male , Proportional Hazards Models , Prospective Studies
10.
J Prev Alzheimers Dis ; 9(2): 331-337, 2022.
Article in English | MEDLINE | ID: mdl-35543007

ABSTRACT

BACKGROUND: Matrix metalloproteinase 9 (MMP-9) has been reported to be correlated with declines in hippocampal volume and cognitive function in ApoE4-positive MCI patients. OBJECTIVES: The present study was aimed to investigate the effects of plasma matrix MMP-9 on the conversion risk between mild cognitive impairment (MCI) patients with and without ApoE4. DESIGN AND SETTING: Retrospective observational study using the data extracted from the Alzheimer's Disease Neuroimaging Initiative database. PARTICIPANTS: We included 211 ApoE4-positive MCI subjects (ApoE4+ MCI) and 184 ApoE4-negative MCI subjects (ApoE4- MCI). MEASUREMENTS: We obtained demographic and data including plasma MMP-9 levels at baseline and longitudinal changes in Clinical Dementia Rating (CDR) up to 15 years. We compared conversion rates between ApoE4+ MCI and ApoE4- MCI by the Log-rank test and calculated the hazard ratio (HR) for covariates including age, sex, educational attainment, drinking and smoking histories, medications, and plasma MMP-9 levels using a multiple Cox regression analysis of ApoE4+ MCI and ApoE4- MCI. RESULTS: No significant differences were observed in baseline plasma MMP-9 levels between ApoE4+ MCI and ApoE4- MCI. High plasma MMP-9 levels increased the conversion risk significantly more than low plasma MMP-9 levels (HR, 2.46 [95% CI, 1.31-4.48]) and middle plasma MMP-9 levels (HR, 1.67 [95% CI, 1.04-2.65]) in ApoE4+ MCI, but not in ApoE4- MCI. CONCLUSION: Plasma MMP-9 would be the risk of the future conversion to dementia in ApoE4+ MCI.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/genetics , Apolipoprotein E4/genetics , Disease Progression , Humans , Matrix Metalloproteinase 9 , Neuroimaging
11.
Orthopade ; 38(8): 681-8, 2009 Aug.
Article in German | MEDLINE | ID: mdl-19657619

ABSTRACT

Periprosthetic infection remains a major complication in arthroplasty; increasing numbers of primary and revision arthroplasties are being followed by increasing numbers of periprosthetic infections. In cases of possible infection, the surgeon must have a treatment concept that can be individually adjusted. Diagnosis is a challenge and should include a variety of investigations. In early and secondary infections, component retention can be successful. Surgical debridement is the key to success. All late and chronic infections should be treated by explantation of all components because of infection with biofilm-producing microbes. The individual patient's situation and the surgeon's experience should determine whether to choose direct single-stage or two-stage revision. New diagnostic and therapeutic procedures can improve outcomes but cannot replace the need for prophylactic efforts.


Subject(s)
Arthroplasty, Replacement, Hip/adverse effects , Debridement/methods , Hip Prosthesis/adverse effects , Joint Instability/surgery , Prosthesis Failure , Prosthesis-Related Infections/etiology , Prosthesis-Related Infections/therapy , Humans , Joint Instability/complications , Patient Selection , Reoperation/instrumentation , Reoperation/methods
12.
Eur Cell Mater ; 16: 47-55, 2008 Oct 23.
Article in English | MEDLINE | ID: mdl-18946860

ABSTRACT

In regenerative medicine, there is an approach to avoid expansion of the mesenchymal stem cell (MSC) before implantation. The aim of this study was to compare methods for instant MSC therapy by use of a portable, automatic and closed system centrifuge that allows for the concentration of MSCs. The main outcome measures were the amount of MSCs per millilitre of bone marrow (BM), clusters of differentiation (CD), proliferation and differentiation capacities of the MSC. A volume reduction protocol was compared to the traditional laboratory methods of isolation using a Ficoll gradient and native BM. Fifty millilitres of BM were obtained from haematologically healthy male Caucasians (n=10, age 8 to 49 years). The number of colony forming units-fibroblast (CFU-F)/ml BM was highest in the centrifuge volume reduction protocol, followed by the native BM (not significant), the centrifuge Ficoll (p=0.042) and the manual Ficoll procedure (p=0.001). The MSC of all groups could differentiate into the mesenchymal lineages without significant differences between the groups. The CD pattern was identical for all groups: CD13+; CD 44+; CD73 +; CD90+; CD105+; HLA-A,B,C+; CD14-; CD34-; CD45-; CD271-; HLA-DR-. In a further clinical pilot study (n=5) with 297 ml BM (SD 18.6), the volume reduction protocol concentrated the MSC by a factor of 14: there were 1.08 x 10(2) MSC/ml BM (standard deviation (SD) 1.02 x 10(2)) before concentration, 14.8 x 10(2) MSC/ ml BM (SD 12.4 x 10(2)) after concentration, and on average 296 x 10(2) MSC (SD 248.9 x 10(2), range 86.4-691.5 x 10(2)) were available for MSC therapy. The volume reduction protocol of the closed centrifuge allows for the highest concentration of the MSC, and therefore, is a promising candidate for instant stem cell therapy.


Subject(s)
Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cells/cytology , Regenerative Medicine/methods , Bone Marrow Cells/cytology , Cell Differentiation , Cell Proliferation , Cell Separation/methods , Centrifugation , Ficoll , Humans
13.
Chirurg ; 79(10): 937-43, 2008 Oct.
Article in German | MEDLINE | ID: mdl-18818895

ABSTRACT

Lumbar total disc replacement is an increasingly common way of treating degenerative lumbar disc disease while preserving mobility. The aim of this analysis was to survey evidence-based data to classify the procedure. Based on a MEDLINE inquiry, 38 clinical trials dealing with lumbar total disc replacement were selected and analyzed by the criteria of indication, preoperative procedure, and clinical follow-up. These data represent 3,180 patient-related evaluations with follow-up of 5.9 to 204 months. We also included ten retrospective studies. Patient satisfaction was a mean of 90.73%, and the Oswestry Disability Index and Visual Analog Scale were significantly lower. High rates of revision surgery, explantation surgery, and secondary fusions are linked to wrong preoperative indication. According to evidence criteria, the results show that lumbar total disc replacement is a safe procedure with a high rate of success. There is clear evidence that both imprecise indication and the choice of too-small implants significantly reduce the prospect of surgical success and increase the rates of reintervention.


Subject(s)
Arthroplasty, Replacement/instrumentation , Intervertebral Disc/surgery , Lumbar Vertebrae/surgery , Prostheses and Implants , Spondylosis/surgery , Disability Evaluation , Evidence-Based Medicine , Follow-Up Studies , Humans , Multicenter Studies as Topic , Pain Measurement , Postoperative Complications/etiology , Prosthesis Design , Randomized Controlled Trials as Topic
14.
Clin Nephrol ; 67(1): 12-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17269594

ABSTRACT

BACKGROUND: Maxacalcitol is a vitamin D analogue, which is administered intravenously for secondary hyperparathyroidism in dialysis patients as well as calcitriol. However, few dose-comparison clinical studies have been reported for these drugs. The present multicenter, randomized crossover study was conducted to determine the equivalence of maxacalcitol and calcitriol doses. METHODS: Subjects comprised 31 patients on chronic hemodialysis with secondary hyperparathyroidism who had not received maxacalcitol or calcitriol in the previous 3 months. Patients were randomly divided into two groups, and maxacalcitol or calcitriol was administered in a crossover design for 12 weeks each. Maxacalcitol and calcitriol doses were adjusted based on serum levels of calcium and intact parathyroid hormone. RESULTS: After the 12-week maxacalcitol/calcitriol administration, there were no significant differences in levels of calcium (maxacalcitol 2.40+/-0.22 mmol/1 (9.6+/-0.9 mg/dl), calcitriol 2.42 + 0.25 mmol/l (9.7+/-1.0 mg/dl), p = 0.71), phosphate (maxacalcitol 1.97 + 0.42 mmol/l (6.1+/-1.3 mg/dl), calcitriol 2.00+/-0.48 mmol/l (6.2+/-1.5 mg/dl), p = 0.64), intact parathyroid hormone (maxacalcitol 267+/-169 pg/ml, calcitriol 343+/-195 pg/ml, p = 0.11) in serum or other bone-metabolic parameters such as serum alkaline phosphatase. The doses ofmaxacalcitol and calcitriol were 49.3+/-23.7 microg/month and 9.0+/-3.8 microg/month, respectively, and maxacalcitol : calcitriol dose ratio was 5.5: 1. No severe adverse reactions were seen for either maxacalcitol or calcitriol during the study period. CONCLUSIONS: Comparable therapeutic efficacy can be obtained in the treatment of secondary hyperparathyroidism using either maxacalcitol or calcitriol at a dose ratio of 5.5 : 1.


Subject(s)
Calcitriol/analogs & derivatives , Calcitriol/therapeutic use , Hyperparathyroidism, Secondary/drug therapy , Renal Dialysis , Vitamin D/analogs & derivatives , Aged , Calcium/blood , Cross-Over Studies , Dose-Response Relationship, Drug , Female , Humans , Hyperparathyroidism, Secondary/blood , Hyperparathyroidism, Secondary/etiology , Male , Middle Aged , Parathyroid Hormone/blood
15.
J Mol Biol ; 240(2): 155-66, 1994 Jul 08.
Article in English | MEDLINE | ID: mdl-8027999

ABSTRACT

The three-dimensional structure of erabutoxin b, a short-chain neurotoxic peptide purified from the venom of the sea snake Laticauda semifasciata, was determined in aqueous solution by two-dimensional proton nuclear magnetic resonance and simulated annealing-based calculations. On the basis of 883 assigned nuclear Overhauser effect (NOE) connectivities, 676 final distance constraints were derived and used together with 38 torsion angle (phi, chi 1) constraints, four distance constraints derived from disulfide bridges and 30 distance constraints derived from hydrogen bonds. A total of 14 converged structures were obtained from 50 runs of calculations. The atomic root-mean-square difference about the mean coordinate positions (excluding the residues 18 to 22) is 0.60 A for backbone atoms (N, C alpha and C'). The protein consists of a core region from which three finger-like loops emerge outwards. It includes a short, two-stranded antiparallel beta-sheet of residues 2 to 5 and 13 to 16, a three-stranded antiparallel beta-sheet involving residues 23 to 30, 35 to 41 and 50 to 56, and four disulfide bridges in the core region. Comparison with two crystal structures of erabutoxin b at 1.4 A and 1.7 A resolution indicated that the solution and the crystal structures were very similar, but less defined regions were observed at the localized region of the tip of the central loop and the outside of the third loop in solution. Other short-chain alpha-neurotoxins showed structural characteristics similar to those of erabutoxin b.


Subject(s)
Erabutoxins/chemistry , Neurotoxins/chemistry , Protein Structure, Tertiary , Amino Acid Sequence , Crystallography, X-Ray , Hydrogen Bonding , Magnetic Resonance Spectroscopy , Models, Molecular , Molecular Conformation , Molecular Sequence Data , Protein Structure, Secondary , Solutions
17.
Int J Radiat Oncol Biol Phys ; 51(3): 666-70, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11597807

ABSTRACT

PURPOSE: Stereotactic radiotherapy (SRT) is highly effective for brain metastases from non-small-cell lung cancers (NSCLCs). As such, primary lesions of NSCLC may also be treated effectively by similar focal high-dose SRT. METHODS AND MATERIALS: Between October 1994 and June 1999, 50 patients with pathologically proven T1-2N0 M0 NSCLC were treated by CT-guided frameless SRT. Of these, 21 patients were medically inoperable and the remainder were medically operable but refused surgery. In most patients, SRT was 50-60 Gy in 5-10 fractions for 1-2 weeks. Eighteen patients also received conventional radiotherapy of 40-60 Gy in 20-33 fractions before SRT. RESULTS: With a median follow-up period of 36 months (range 22-66), 30 patients were alive and disease free, 3 were alive with disease, 6 had died of disease, and 11 had died intercurrently. Local progression was not observed on follow-up CT scans in 47 (94%) of 50 patients. The 3-year overall survival rate was 66% in all 50 patients and 86% in the 29 medically operable patients. The 3-year cause-specific survival rate of all 50 patients was 88%. No definite adverse effects related to SRT were noted, except for 2 patients with a minor bone fracture and 6 patients with temporary pleural pain. CONCLUSIONS: SRT is a very safe and effective treatment for Stage I NSCLC. Additional studies involving a larger patient population and longer follow-up periods are warranted to assess this new treatment for early-stage lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/surgery , Radiosurgery/methods , Tomography, X-Ray Computed , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/surgery , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/surgery , Female , Humans , Lung Neoplasms/diagnostic imaging , Male , Middle Aged , Radiography, Interventional , Radiotherapy Dosage , Treatment Outcome
18.
Int J Radiat Oncol Biol Phys ; 48(2): 443-8, 2000 Sep 01.
Article in English | MEDLINE | ID: mdl-10974460

ABSTRACT

PURPOSE: To evaluate intrafractional tumor position stability during computed tomography (CT)-guided frameless stereotactic radiation therapy (SRT) for lung or liver cancers, we checked repeated CT scanning, with a fusion of CT and linear accelerator (FOCAL) unit. METHODS AND MATERIALS: The FOCAL unit is a combination of a linear accelerator (Linac), CT scanner, X-ray simulator (X-S), and carbon table, and is designed to achieve CT-guided SRT with daily CT positioning followed by immediate irradiation while patients keep reduced shallow respirations. To evaluate intrafractional tumor position stability, 50 lung or liver lesions in 20 patients were checked by repeated CT scanning just before and after irradiation, and the obtained images were compared. RESULTS: There was no case with the intrafractional error judged to be greater than 10 mm. In 68% of cases, the intrafractional positioning errors were negligible (0-5 mm). CONCLUSIONS: Using the FOCAL unit, SRT for lung or liver cancers could be performed with intrafractional positioning errors not greater than 10 mm.


Subject(s)
Liver Neoplasms/surgery , Lung Neoplasms/surgery , Particle Accelerators , Radiosurgery/methods , Tomography, X-Ray Computed/instrumentation , Equipment Design , Humans , Liver Neoplasms/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Radiosurgery/instrumentation
19.
Opt Express ; 9(1): 2-6, 2001 Jul 02.
Article in English | MEDLINE | ID: mdl-19421266

ABSTRACT

A novel spatial light modulator (SLM) made of an array of fused-silica plates was developed for the purpose of feedback control for intense femtosecond laser pulses over a wide spectral range. Dispersion compensation for 20-fs pulses from a Ti:sapphire oscillator was successfully demonstrated using the SLM with an adaptive feedback control system. The SLM was also applied to the output pulses from a Ti:sapphire amplifier for compensation of material.

20.
Phys Rev Lett ; 84(17): 3847-50, 2000 Apr 24.
Article in English | MEDLINE | ID: mdl-11019221

ABSTRACT

Self-compression of high-intensity femtosecond pulses has been observed in a number of atomic and molecular gases and solid bulk material. The evolution of the femtosecond pulse parameters during the self-compression has been studied under a variety of experimental conditions. Generation of spatiotemporal solitons has been achieved by the combined action of self-compression and self-focusing.

SELECTION OF CITATIONS
SEARCH DETAIL